Eric E. Williams, Pharm.D. Partner
Inventors, entrepreneurs and innovators consistently turn to Eric for advice on how to protect their ideas. Eric is skilled in preparing and prosecuting patent applications and has experience in managing extensive patent portfolios in the U.S. and abroad. Valued for his ability to quickly understand complex technologies and to retain extensive, detailed information, Eric has proven the ability to guide clients through challenges and to devise novel, practical approaches to problem-solving that align with technological goals and business strategies.
Eric advises on IP portfolio development and management, as well as IP-related diligence initiatives in mergers, acquisitions, and securities offerings. He counsels clients on domestic and international patent preparation and prosecution before the U.S. Patent and Trademark Office and gives advice on patent landscape analyses. In addition, Eric prepares legal opinions regarding patent invalidity and noninfringement, and advises on academic-related technology transfers by assessing patentability, preparing patent applications, and applications to grant.
Notably, Eric focuses in the pharmaceutical industry and prepares patent term extension (PTE) applications for FDA-approved products. In the area of higher education, he works extensively with both U.S.-based and international universities on protecting their IP on a global scale. Having grown up with a strong agricultural background, Eric enjoys working with ag and food companies on IP involving animal health, ag biotech and food products.
While earning his Pharm.D., Eric conducted research on the ErbB family of tyrosine kinase receptors. He is the co-author of multiple journal articles and several symposium abstracts published from this research. He is also a licensed pharmacist in Indiana.
In addition, Eric performed a postdoctoral fellowship in clinical research at the University of North Carolina-Chapel Hill and GlaxoSmithKline, where he investigated CYP450 metabolism in various patient groups, including healthy volunteers, liver transplant donors, and liver transplant recipients. At GlaxoSmithKline, he also participated in the design of Phase II/III clinical trials in the neuroscience therapeutic area, including interactions with the U.S. Food and Drug Administration (FDA) and the foreign regulatory agencies.
Moreover, Eric has experience as a medical information associate for Eli Lilly and Company. In this role, he provided support to Lilly’s global affiliates and authored global response documents for Strattera® to answer clinical and regulatory product inquiries.
Professional and Community Involvement
Member, Association of University Technology Managers (AUTM)
Member, Biotechnology Innovation Organization (BIO)